Drugs / HLX03
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT03357939 | Jan 2017 → Sep 2018 | immune system disorder | Shanghai Henlius Biotech | Completed | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03316781 | Oct 2017 → Jul 2018 | psoriasis | Shanghai Henlius Biotech | Completed | Met primary |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-10-29 | Shanghai Henlius Biotech | The Results of the Phase 3 Study of Henlius’ Adalimumab Biosimilar HLX03 Presented on EADV 2020 henlius.com ↗ |
| 2019-07-04 | Shanghai Henlius Biotech | Henlius Has Completed the Phase 3 Study of Its Adalimumab Injection HLX03 henlius.com ↗ |
| 2018-11-29 | Shanghai Henlius Biotech | Henlius Completed Data Analysis of the Phase 1 Study for Its HLX03 henlius.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03316781 ↗ |
| Action | Inhibit | “Anti-TNFα” NCT03316781 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-TNFα Human Monoclonal Antibody Injection (HLX03)” NCT03316781 ↗ |
| Route | Subcutaneous | “80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.” NCT03316781 ↗ |
| Target | TNF | “Anti-TNFα Human Monoclonal Antibody” NCT03316781 ↗ |